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ClinicalMethodDesign and Methods of the Korean Organ
Transplantation Registry
Jaeseok Yang, MD, PhD,1 Jong Cheol Jeong, MD,2 Joongyub Lee, MD, PhD,3 Young Hoon Kim, MD, PhD,4
Hyo Chae Paik, MD, PhD,5 Jae-Joong Kim, MD, PhD,6 Hyun-young Park, MD, PhD,7 Myoung Soo Kim, MD, PhD,8
and Curie Ahn, MD, PhD,9 on behalf of the KOTRY study groupBackground. Beneficial aspects of solid organ transplantation, which encompass survival benefit, improved quality of life, and
cost efficacy, have been clearly demonstrated. However, regional and ethnic differences require further studies to identify prognos-
tic factors and transplant outcomes against various backgrounds. After previous efforts of a nationwide, retrospective study on the
kidney transplant outcomes in Korea, a new prospective-designed version of the Korean Organ Transplantation Registry (KOTRY)
was launched in 2014.Methods. Cohorts of kidney, liver, heart, lung, and pancreas transplantation were developed. Data on
demographics, comorbid conditions, laboratory tests, including tissue typing and panel reactive antibody tests, immunosuppres-
sive regimen followed, concentration and dosage of immunosuppressants, allograft rejection type, infectious events, cardiovascu-
lar outcomes, malignancies, donor comorbidity, and outcomes of living donors are collected. Longitudinal data collection is based
on a regular annual interval, and blood samples are collected before organ transplantation and again at 1 and 3 years posttrans-
plantation. To enhance data quality, a predefined data verification system operates on aWeb-based database, and transplant cen-
ter users receive regular education about updates. Data are cleansed thrice a year, and feedback given to centers about outlier
values andmissing data. Annual auditing is conducted.Results.Currently, 59 centers are participating in KOTRY. The estimated
annual enrollment is more than 2000 cases. Conclusions. KOTRY, as a systematic Korean transplant cohort, is expected to
provide important information on Asian organ transplantation. The processes used to establish KOTRY provide a good model
for launching new nationwide transplant cohort studies.
(Transplantation Direct 2017;3: e191; doi: 10.1097/TXD.0000000000000678. Published online 7 July, 2017.)Solid organ transplantation is a lifesaving treatment op-tion for patients with organ failure, improves quality
of life, and reduces health-care cost.1-6 However, regional
and ethnic differences require further studies to identifyReceived 31 January 2017. Revision received 4 February 2017.
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backgrounds. For instance, amajor cause of death inWestern
kidney transplantation recipients is cardiovascular disease;
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2 Transplantation DIRECT ■ 2017 www.transplantationdirect.comdisease was lower than expected, suggesting that the optimal
management and immunosuppression protocol might differ
for patients of different ethnic and regional backgrounds.7,8
According to a report from the Global Database on dona-
tion and transplantation (GODT), living donors represent
the major source of transplanted organs in Asia. In the past,
living liver or kidney transplantation were in the majority
in Korea. However, since the legislation of transplantation
law in 1999, the process of deceased donor organ transplan-
tation has been systematized, by adopting a centralized organ
allocation system, introducing an organ-procurement organi-
zation system, and implementing a public organ donation
agency.9,10 All these efforts have led to a nearly eightfold in-
crement in deceased donor organ transplantation, from 233
cases in 2000 to 1989 cases in 2015, in parallel with the in-
crement of deceased donors from 1.09 permillion population
in 2000 to 9.72 per million population in 2015.
Along with the expansion of transplantation quantity,
many efforts have been made to study nationwide post-
transplant outcomes; these included the retrospective Korean
Organ Transplantation Registry (Retro-KOTRY) study.11
The Retro-KOTRY was initiated by the Korean Society of
Transplantation, and the study included 91.9% of total kid-
ney transplantations in Korea between January 2009 and
September 2012. The 1- and 3-year survival rates were
98.9% and 96.0%, and graft survival was 98.6% and
93.7%, respectively. Through that nationwide study, we were
able to identify epidemiological trends, such as a rapid increase
in ABO-incompatible kidney transplantation, with utilization
of more spousal donors, and a more liberal or routine use of
the expanded donor criteria. After previous efforts, we are
now conducting a second retrospective study for the period be-
tween October 2012 and March 2014. More importantly, a
new prospective-designed version of KOTRY was launched
in 2014 (Figure 1). KOTRY is composed of 5 solid organ
transplantation cohorts, including those of kidney, liver,
heart, lung, and pancreas transplants. Herein, we present the
design and protocol of KOTRY, which is expected to answer
the following fundamental questions:
1. What is the primary indication for solid organ transplanta-
tion in the Korean population?
2. How severe is the comorbidity burden of solid organ
transplantation?
3. What are the immediate postsurgical risks of solid organ
transplantation?FIGURE 1. Overview of the KOTRY according to the history of registry4. What is the long-term course of solid organ transplantation?
5. What is the most common cause of death after solid organ
transplantation?
6. What is the most common cause of allograft failure?
7. What is the prevalence of induction and maintenance
immunosuppression?
8. What is the prevalence of posttransplant comorbidities?
9. What are the genetic factors associated with the deteriora-
tion of allograft function?
10. What are the biomarkers that predict the deterioration of al-
lograft function?
11. What are the short- and long-term courses of living donors?
METHODS AND RESULTS
Study Organization
The KOTRY consists of 59 participating centers (30 cen-
ters for kidney, 15 for liver, 4 for heart, 5 for lung, 5 for pan-
creas), a central coordination unit, and a medical research
coordinating center (MRCC). The organizational structures
include the organ-specific committee, executive committee,
and steering committee. A central coordination unit leads
the study process, checks enrollment status weekly, and gives
feedback to the participating centers. TheMRCC is in charge
of data validation and statistical consultation. The Korean
National Research Institute of Health (KNIH) developed
and offered a globalWeb-based electronic data capturing sys-
tem, named iCReaT. KNIHalso participates in the quality as-
surance of the collected data, regular surveillance of study
conductance process, and themanagement and improvement
of the electronic data capturing system. Biospecimen collec-
tion, storage, and quality control are done under contract
with LabGenomics, and part of the deposited biosamples is
transferred to KNIH for backup and future collaboration.
All of the activities are managed by the KOTRY Foundation.
Exclusion Criteria
Recipients younger than 19 years are excluded. Except si-
multaneous pancreas-kidney cotransplantation, those under-
going simultaneous multiorgan transplantation are excluded
to ensure the homogeneity of graft-related outcome.However,
sequential organ transplantations are not excluded. For liver
transplantation, there is no exclusion criterion for age.
Enrollment and Informed Consent
For living donor organ transplantation, both the donor
and recipient are required to register at KOTRY beforedevelopment.
© 2017 Wolters Kluwer Yang et al 3transplantation. The medical records of eligible individuals
are reviewed after receiving their informed consent. Blood
samples are taken for DNA and serum/plasma storage before
transplantation. In deceased donor organ transplantation,
informed consent is taken from the recipient. Under the
strengthened data protection laws of Korea, the social secu-
rity identification number cannot be collected during the
KOTRY. However, for outcome matching with the Korean
national statistical office data or the centralized health insur-
ance claims data, KOTRY receives an optional informed con-
sent for the use of collected data for study of secondary
outcomes. To achieve the best standardized process, we sur-
veyed the opinions of each individual institutional review
board, then submitted a standardized protocol and standard-
ized consent format. This study was approved by the institu-
tional review boards of all participating centers and was
performed in accordance with the Declaration of Helsinki
and the Declaration of Istanbul.
Study Design and Collected Variables
The KOTRY collects solid organ transplantation data to
analyze epidemiological trends, graft-related outcomes, and
patient mortality. In total, data on 5014 variables are col-
lected, which are summarized in Tables 1-3. The kidney as-
pect involves a total of 950 variables, which are composed
of 12 domains of recipient data, 3 domains of donor baseline
data, and 4 domains of living donor follow-up data. The liver
aspect involves 523 variables in total, which consist of 13 do-
mains of recipient data, 4 domains of donor baseline data,
and 3 domains of living donor follow-up. The heart aspect in-
volves 886 variables with 13 domains of recipient data, and
3 domains of donor baseline data. The lung aspect involves
1495 variables with 22 domains of recipient data, and 3 do-
mains of donor baseline data. The pancreas aspect involves
1160 variables with 16 domains of recipient data, 4 domainsTABLE 1.
KOTRY data collection formats for organ recipients: common va
Categories Variables
Demographics Age, gender, ethnicity, date of transplantation, cause o
Comorbidities Height, weight, blood pressure, heart rate, smoking his
hypertension, cardiovascular disease, malignancies
Laboratory assessment CBC, routine chemistry, uric acid, lipid panel, urinalysi
Immunologic assessment ABO/HLA typing, crossmatch, PRA, DSA
Viral markers HBsAg, anti-HBsAb, anti-HCV Ab, anti-CMV Ab, anti-E
Immunosuppressants Induction and maintenance immunosuppressants, con
(calcineurin inhibitors and mTOR inhibitors)
Immediate complications Surgical complications
Discharge data Date of discharge, functioning parameter of transplant
Posttransplant outcomes Allograft rejection, graft failure, infection, patient death
Posttransplant comorbidities Height, weight, blood pressure, heart rate, smoking his
diabetes, hypertension, cardiovascular disease, tube
Biosamples DNA
Serum and plasma
Posttransplant visits within 1 year are differently set among each organ. In kidney transplantation, visits are s
6 months, and in lung transplantation, at 3, 6, and 9 month. Baseline recipients’ DNAs are collected in all o
heart, lung, and pancreas transplantation. In kidney transplantation, posttransplant plasma is additionally c
Less than 1 yr, posttransplant visits within 1 year; A, annual visit; B, baseline visit; CBC, complete blood co
virus surface antigen; anti-HBsAb, anti-hepatitis B virus surface antibody; HCV, hepatitis C virus; HIV, human
panel reactive antibody.of donor baseline data, and 3 domains of living donor
follow-up. Each domain was constructed as a single sheet in
electronic case-report format (CRF) on a Web-based system
(iCReaT). Longitudinal data collection is based on a regular
annual interval. For the collection of early comorbidities
and adverse outcome, different time points were selected ac-
cording to each organ’s clinical characteristics.
To account for the time-varying nature of posttransplanta-
tion comorbidity and to deal with repeated events, we col-
lected posttransplantation comorbidity at every follow-up
visit, which allows the analysis of comorbidity duration, and
the effects of new-onset comorbidities and their duration on
posttransplant outcomes. For example, the duration of tran-
sient new-onset diabetes after transplantation or repeated inci-
dence of cardiovascular disease can be collected. Follow-up
records will be tracked up to the patients’ deaths. However,
graft-related variables, including rejection, graft function,
and general laboratory profiles, will be tracked until graft loss.
To minimize follow-up loss, newsletters regarding registration
status and follow-up performance are periodically sent to each
participating center and a transfer system is used. If a patient
underwent transplantation in center A, and was then followed
up by center B which also participated in KOTRY, the transfer
system allows center B to input that patient’s data. To increase
the follow-up rate of living donors, the KOTRY emphasizes
the importance of follow-up of living donors to each partici-
pating center’s physicians and surgeons.
Biosamples
DNA samples from each donor and recipient are col-
lected before organ transplantation. In kidney, heart, lung,
and pancreas transplantation, sera are collected from recip-
ients at baseline, before transplantation, and again at 1 and
3 years after organ transplantation. Baseline samples are
collected in liver transplantation recipients. From 2017,riables in all organ transplantation
Collection timing
B <1 y A
f organ failure, number of transplantation O
tory, medical history including diabetes,
and selected medication
O
s O O O
O
BV Ab, anti-HIV Ab O
centration of immunosuppressants O O O
O
ed organ O
O O
tory, medical history including new-onset
rculosis, fracture and malignancies
O O
O
O O*
et at 6 month, in liver and heart transplantation, at 1 and 6 month, in pancreas transplantation, at 3 and
rgan transplantation. Posttransplant sera are collected at 1 and 3 years after transplantation in kidney,
ollected at 1 and 3 years after transplantation.
unt; CMV, cytomegalovirus; DSA, donor specific antibody; EBV, Epstein-Barr virus; HBsAg, hepatitis B
immunodeficiency virus; HLA, human leukocyte antigen; mTOR, mechanistic target of rapamycin; PRA,
TABLE 2.
KOTRY data collection formats for organ donors: common variables in all organ transplantation
Collection timing
Categories Variables B A
Demographics Age, sex, relationship to recipients, ethnicity O
Comorbidities Height, weight, blood pressure, heart rate, smoking history, medical history including diabetes, hypertension,
cardiovascular disease, and malignancies
O
Deceased donor profile Deceased donor profile (cause of brain death, inotropics management, vital-supporting devices, cold ischemic time) O
Laboratory assessment CBC, routine chemistry, uric acid, lipid panel, ABO typing, urinalysis O O
Immunologic assessment ABO/HLA typing O
Viral markers HBsAg, anti-HBsAb, anti-HCV Ab, anti-CMV Ab, and anti-EBV Ab O
Living donor outcome Postoperative surgical comorbidities, death, ESRD O
Biosamples DNA O
A, annual visit; B, baseline visit; CBC, complete blood count; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ESRD, end-stage renal disease; HBsAg, hepatitis B virus surface antigen; anti-HBsAb, anti-hepatitis B
virus surface antibody; HDL, high-density lipoprotein; mTOR, mechanistic target of rapamycin inhibitor.
Baseline donors’ DNAs are collected in all organ transplantation.
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before kidney transplantation, and again at 1 and 3 years
postkidney transplant.
Study Outcomes
The primary outcomes are graft failure and patient death.
In kidney transplantation, graft failure is defined as sustained
(more than 3 months) dependency on dialysis. In liver, heart,
and lung transplantation, graft failure is defined as patient
death or retransplantation. Pancreas graft failure is defined
as insulin dependence or death with a full or partially func-
tioning graft.
Pathology data collected included acute or chronic re-
jection12 and other diagnoses, such as virus infection and
calcineurin inhibitor toxicity. Definitions of the major post-
transplantation outcomes are as follows: cardiovascular
disease is defined as cardiovascular death, myocardial infarc-
tion, ischemic heart disease with relevant clinical evidence
(accompanied by therapeutic intervention or objective find-
ings), new-onset congestive heart failure requiring hospital
admission and arrhythmia. Stroke includes nontraumatic
hemorrhagic or ischemic brain disease confirmed by com-
puted tomography ormagnetic resonance image. Tuberculosis
is defined as clinically active disease, as evidenced by typical
chest radiography imaging, microbiological confirmation, orTABLE 3.
Organ-specific information
Organ At baseline
Kidney
Liver Child-Pugh score, MELD/PELD score, donor-recipient liver volumetry, trea
history of hepatocellular carcinoma, surgical type of liver transplantatio
Heart Usage of cardiac assisting device and ventilator, intraoperative cardiopulm
bypass usage
Lung Latent tuberculosis infection (TST, IGRA), bone mineral density, lung size
(donor and recipient), arterial blood gas analysis, donor bronchoscopic
Pancreas C-peptide, anti-GAD antibody, HbA1c, surgical technique (drainage type,
portal vein extension, arterial Y graft, artery and vein anastomosis type
BiPAP, bi-level positive airway pressure; BNP, blood natriuretic peptide; ESRD, end stage renal disease; GA
gamma releasing assay; MELD, model for end-stage liver disease; PELD, pediatric end -stage liver diseastreatment with anti-tuberculosis drugs. Causes of death are
classified into cardiovascular, sudden cardiac death, infection,
malignancy, liver disease, accident, suicide, and others.
Living donor outcomes are collected for living liver or kid-
ney transplantation cases. Death, cause of death, and surgical
morbidities are collected in both liver and kidney transplan-
tations. Newly developed diseases, including diabetes, hyper-
tension, and urinary stones, are collected in living kidney
transplantation donors.
Data Validation
Quadruple layers of data validation are available. First, a
predefined automated data validation system is used at data
input, to prevent simple errors. Automated data validation
system checks are implemented for essential data elements,
to minimize missing variables, and have predefined allowed
data ranges, to reduce extreme outliers due to simple input er-
ror. Additionally, an automated data validation system guide
is used to prevent entering of values inconsistent with other
variables, by opening or blocking data fields in screens after
a logical test of preentered data values. Second, manual data
validation is performed quarterly by the MRCC by feedback
to each participating center. Third, during the outcome ad-
judication meeting, the distribution of major outcomes is
discussed, and outlier values are sent to each investigator.At follow-ups
Allograft biopsy based on Banff reports, living donor outcome
(ESRD, urinary stone, hypertension)
tment
n
Posttransplant rehabilitation status, recurrence of HBV or HCV,
living donor outcome (hepatic morbidity)
onary Serum cardiac markers (NT-proBNP, troponin I and T)
at discharge, echocardiography
measure
exam
Primary graft dysfunction, 6 minutes walking test, pulmonary function
test (spirometry), posttransplant functioning status (tracheostomy,
home O2, BiPAP)
)
Insulin, C-peptide, HbA1c
D, glutamic acid decarboxylase; HbA1c, glycated hemoglobin; HBV, hepatitis B virus; IGRA, interferon
e; TST, tuberculin skin test.
© 2017 Wolters Kluwer Yang et al 5Finally, annual auditing are conducted for all participating
centers, to survey their status, including ethical study con-
ductance, adherence to the standardized study protocol,
and direct comparison of randomly selected data with the
original medical record. These processes are conducted using
the Registries for Evaluating Patient Outcomes tool by the
Agency for Healthcare Research Quality.13
Building Statistical Analysis Files and Response to the
Data Request
A statistical analysis file is built thrice a year, after a quar-
terly data cleansing process.When the participating center re-
quests their own data, the last validated statistical analysis
file is sent to the requesting center. We aim at a feedback time
of 4 hours, in parallel with the standard operating protocol of
Scientific Registry of Transplant Recipients.14 To request all
centers’ data, items of the requested variable are released as
a deidentified set (at patient- and center-level) after approval
of the organ committee in KOTRY, after review of the study
proposal. Each center has access to themain database located
in KNIH and can download their own data set; however, this
is not recommended due to network traffic and incomplete-
ness of data validation. Currently, KOTRY focuses on the
ease of data cleansing through an attached online automatic
plotting system, and on giving more informative feedback
to the participating center, and finally on enforcing informa-
tion technology-security issues.
Statistical Considerations
Descriptive data analysis will be conducted for baseline
characteristics. To study outcomes, time-to-event analysis
will be primarily used. Life-table methods or Kaplan-Meier
curves will be used to represent allograft or patients’ survival,
and time to major outcomes (cardiovascular disease, cancer,
infection, acute rejection, and so on). For the competing
nature of outcome events (eg, patient death vs cancer oc-
currence), competing risk models will be adopted for re-
gression modeling.15 The multilevel characteristics of data
were adjusted using a shared-frailty model,16 in which ad-
justment should be made for time-dependent confounders
or different data hierarchies. To encompass the wide variabil-
ity of allograft functional decline, the Bayesian smoother will
be used.17 Longitudinal allograft functional changes and as-
sociated factors will be analyzed using a mixed linear model.TABLE 4.
Minimum detectable increase in relative risk of graft survival, pat
Organ (expected enrollment
number by 2019)
Survival
outcomes
Estimated no. outcomes by
based on observed even
Kidney Transplant (12 000) Graft 1379
Patient 736
Liver transplant (3900) Graft 839
Patient 636
Heart transplant (570) Graft 130
Patient 119
Lung transplant (150) Graft 48
Patient 51
Pancreas transplant (150) Graft 41
Patient 25Because the format of follow-up data is a repeated panel
structure, the marginal structural model with time-varying
confounder adjustment can be applied.18
Statistical Power
From 2017, new annual enrollments are estimated as 1200
for kidney, 700 for liver, 100 for heart, and 30 for lung and
pancreas transplantation, respectively. In kidney transplanta-
tion, the previous Retro-KOTRY collected the data of 4987
kidney recipients, and the effort is ongoing to collect the
missing information (approximately 1200 kidney recipient’s
data) from the end of the previous Retro-KOTRYenrollment
and the launch of the prospective KOTRY-kidney (Figure 1).
With the assumption of attaining the patient enrollment plan,
Table 4 shows the minimum hazard ratios (HRs) detectable
at a given prevalence level of risk factors by 2019, using
exponential models based on the 20-year patient and graft
survival for solid organ transplants from the Organ Pro-
curement and Transplantation Network.19 The KOTRY-
kidney cohort is estimated to detect a relative risk of 1.05
and 1.06 for graft survival and patient survival, respectively,
with a 50% prevalent risk factor, at 5% alpha error and
20% beta error in an analysis using a Cox regression model
(Table 4). Similarly, the KOTRY-liver, heart, lung, and pan-
creas cohorts will be able to detect HRs of 1.11, 1.32, 1.87,
and 1.82, respectively, for graft survival.
Representativeness
In 2015, the total numbers of organ transplant centers
and KOTRY-participating centers were as follows: for kid-
ney, 30 of 66 centers participated in KOTRY; for liver, 15
of 44; for heart, 4 of 13; for lung, 5 of 7; for pancreas, 5
of 9. As large-volume centers joined KOTRY, the numbers
of organ transplantations performed in KOTRY-participating
centers were predominantly as follows: for kidney, 1565
(82.8%) of 1891; for liver, 1073 (77.1%) of 1392; for heart,
127 (87.6%) of 145; for lung, 61 (95.3%) of 64; for pan-
creas, 51 (86.4%) of 59.DISCUSSION
The KOTRY is a prospective nationwide cohort. KOTRY
will enroll new solid organ transplant patients and donors,
collect detailed epidemiological data, and conduct rigorous
data validation with the goal of providing the infrastructureient survival and acute rejection
2019
ts
Detectable statistically significant minimum of HRs
Risk factor with
10% prevalence
Risk factor with
20% prevalence
Risk factor with
50% prevalence
1.09 1.07 1.06
1.09 1.07 1.05
1.18 1.13 1.11
1.17 1.13 1.10
1.51 1.38 1.32
1.50 1.38 1.31
2.34 1.98 1.87
2.37 2.00 1.89
2.25 1.92 1.82
2.09 1.81 1.72
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will collect detailed information regarding organ transplanta-
tion; however, every effort will be made to keep the variables
concise and precise. Asia is a rapidly changing region, not only
in terms of its fast-growing economy, but also in terms of
lifestyle, disease prevalence, and an aging population struc-
ture.21,22 In Korea, changes are also found in the trans-
plantation field. Deceased donor kidney transplantation
comprised 20% of total kidney transplantation in 2000;
however, it reached 45% in 2015. ABO-incompatible kid-
ney transplantation has expanded rapidly,11 accounting for
almost one third of living kidney transplantations (2016 in-
terim data of KOTRY). The role of the registry in managing
this changing epidemiology is invaluable.
A number of successful models for a solid organ transplant
registry exists.23 The Collaborative Transplant Study (CTS)
is a global transplant registry, contributing to the interna-
tional reference source of transplant-related outcome study.
CTS is based on voluntary international communication,
and has contributed to the discovery of the clinical impor-
tance of HLAmismatching, and the study of rare-disease out-
comes.24 The Scientific Registry of Transplant Recipients has
presented good examples of data linkage analysis with an ad-
ministrative database, allowing a change in the organ alloca-
tion system based on scientific evidence.14 Recent studies on
living donor outcomes are also based on data matching,
based on the United States Renal Data System reports, and
are used for the establishment of further guidance.25,26
The Australia and New Zealand Dialysis and Transplant
(ANZDATA) registry is the national registry of Australia
and New Zealand for dialysis and kidney transplantation.27
In addition to many published articles, ANZDATA is also in-
volved in quality assurance issues in countries, and gives
feedback to the participating center.28,29 International Regis-
try for Heart and Lung Transplantation is largest worldwide
repository of heart and lung transplant activity.30 The Swiss
Transplant Cohort Study is a recently-launched cohort, which
has very similar characteristics toKOTRY.31 TheGlobalData-
base on donation and transplantation is a database for the
infrastructure and legislation for global transplantation,32
which does not collect patient-level data.
The KOTRY is designed to play an academically oriented
role, rather than act as an administrative registry. KOTRY
includes the cause of death and the reasons of graft loss,
to enable studying of the underlying mechanisms. KOTRY
also collects detailed profiles on immunosuppression, to pro-
duce relevant data about optimized immunosuppression.
The KOTRY attempts to collect longitudinal data: various
long-term metabolic outcomes are collected, and the time-
dependent change of covariates is also gathered, enabling
more sophisticated analyses, including competing risk analy-
sis, multilevel modeling, or marginal structural analysis.
As a mother cohort, KOTRY has many strengths. A large
sample size is the most important feature as a mother cohort,
because it offers a higher probability of obtaining a matched
control. To ensure faster accumulation of data, KOTRY
plans to merge previous Retro-KOTRY data into the pro-
spective KOTRY kidney data in the future. Preciseness is an-
other strength of KOTRY: a well-defined phenotype is more
relevant than an administrative database or a claims data-
base. The KOTRY focuses on width rather than depth, to en-
compass as many centers as possible; however, it also hasdetails on selected features, such as biopsy reports describing
the Banff staging system, infection sheets reporting causative
organisms, and a detailed description of malignancy, including
the location and type. With such details, KOTRY can effi-
ciently provide amatched control for any future study. Playing
a role as a study platform is another goal of KOTRY, and
KOTRY is expected to provide the basis for future studies.
These characteristics are also strengths of a biosample co-
hort. All samples in KOTRYare centralized in terms of qual-
ity assessment and storage. The samples can be used as a
whole for a validation study of potent candidate biomarkers,
or be used only in selected cases for explorative studies in
a nested case-control study design. All analyzed data will
be stored in the KOTRY biomarker database, which can
serve as a systems biology database, such as a phenotype-
genotype database. Additional stepwise approaches are also
possible, because KOTRY stores various types of samples
to be prepared for multiomics studies.33,34 However, some is-
sues, such as controlling for batch effect and early depletion
of common phenotype samples, are challenges that KOTRY
needs to overcome. Because biosamples are very limited re-
sources, the steering committee of KOTRY has decided not
to use a certain quota of biosamples in the preparation for
long-term outcome analysis.
To summarize, the strengths of KOTRY are as follows:
(1) It provides a systematic prospective solid organ transplant
cohort in the Asian population. (2) It offers good phenotype
characterization based on a detailed clinical history. (3) It val-
idates data rigorously. (4) It offers statistical power from a
large cohort, which enables the study of rare outcomes.
(5) It is expected to serve as a mother cohort for future spe-
cific subcohorts. (6) It acts as a centralized collection, storage,
and quality control facility for biosamples. (7) It collects liv-
ing donor outcomes.
The authors expect that in practice, KOTRY will be the
representative standard cohort for producing parametric in-
dices regarding organ transplantation in Korea and for pro-
viding standard control data for other specified studies.
Serving as a common data warehouse may allow participat-
ing researchers to bemore involved in data validation of their
own. Furthermore, as a systems biology database, KOTRY
can deposit genotype data and biomarker data alongwith de-
tailed phenotype data. As a forum of group discussion,
KOTRY can produce study questions that are priorities in
Korean and Asian transplantation. Finally, KOTRY can play
a public role by providing an annual report to the general
population and can perform a quality assurance role in the
long term. To translate these hopes into reality, continuous
participation and pertinent efforts are needed, and much re-
mains to be done.
In conclusion, the KOTRY is a nationwide solid organ
transplantation cohort registry in Korea. To serve as a valu-
able national and international resource, continuous efforts
are needed. The KOTRY, as a systematic Korean transplant
cohort, is expected to provide important information on
Asian organ transplantation. The processes used to establish
the KOTRY represent a goodmodel for launching of new na-
tionwide transplant cohort studies.
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